Live news related to AB SCIENCE stock (FR0010557264): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
AB Science announces the identification of a plasma biomarker capable of assessing the activity of masitinib in the treatment of amyotrophic lateral s…
AB Science announces that the U.S. Food and Drug Administration has granted Minor Use in Major Species (MUMS) status to its Masivet® treatment for the…
AB Science announced that it has received a patent acceptance notification from the U.S. Patent Office for a patent covering the use of masitinib in t…
AB Science has announced that the Japanese Patent Office has issued a patent protecting the use of masitinib in the treatment of progressive forms of …
The French biopharmaceutical group AB Science announced on the evening of January 7 a fourth consecutive clinical response observed with the combinati…
AB Science has reported the results of its phase 1 trial combining AB8939 and venetoclax in patients with refractory or relapsed acute myeloid leukemi…
AB Science announces that the United States Patent Office has issued a notice of allowance for a patent on the use of masitinib in the treatment of si…
AB Science announced on December 18 that Maxim Group, an American investment banking services firm, has initiated coverage of its stock with a buy rec…
AB Science announces the publication of a preclinical study on bioRxiv regarding AB8939, a new synthetic molecule developed to treat refractory acute …
AB Science has shared new results regarding masitinib, demonstrating clinical benefits in the treatment of amyotrophic lateral sclerosis (ALS), accord…
